Special Issue "Molecular Therapeutics of Breast Cancer"

A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "Molecular Genetics and Genomics".

Deadline for manuscript submissions: 20 April 2022.

Special Issue Editor

Dr. Amir Sonnenblick
E-Mail Website
Guest Editor
1. Dept Oncol, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Interests: breast cancer; molecular therapeutics; targeted therapy

Special Issue Information

Dear Colleagues, 

Breast cancer (BC) has been diagnosed since ancient times. Hippocrates, "the father of Western medicine", first suggested that BC was a systemic disease. The fundamentals of his theory stood for more than 2000 years until 1757 when Henri Le Dran, a French physician, suggested that surgical removal of the tumor could cure BC as it was a local disease with local origin. Extensive clinical and basic research have conceptually changed the way we perceive breast cancer, shifting from an emphasis on local therapy to an emphasis on systemic treatment options. In recent years, different molecular alterations governing BC progression have led to potential novel targeted therapies. The present Special Issue will focus on the evolution of BC treatment philosophy in the last years and the shift from an emphasis on local therapy to an emphasis on systemic treatment options and molecular therapeutics.

Dr. Amir Sonnenblick
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • breast cancer
  • molecular therapeutics
  • systemic treatment
  • targeted therapies
  • PIK3CA
  • mTORC
  • PDL1/PD1
  • ER
  • HER2
  • prognostic markers
  • predictive markers

Published Papers

This special issue is now open for submission, see below for planned papers.

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

1. title: RANK-c expression in ER-negative breast cancer cells alters sensitivity to tyrosine kinase inhibitors.
Back to TopTop